Pharma News Intelligence August 2, 2024
AbbVie is expanding its neuroscience portfolio through its acquisition of Cerevel Therapeutics.
On August 1, 2024, AbbVie concluded its acquisition of Cerevel Therapeutics, a clinical-stage neuroscience company, to expand its neuroscience and psychiatric medicine portfolio. The deal was finalized at $45 per share.
According to the company’s press release, Cerevel’s pipeline includes multiple neurological and psychiatric drugs in development for various conditions such as schizophrenia, Parkinson’s disease, mood disorders, and more.
Through this acquisition, Cerevel will function under AbbVie, which could offer the company the support of a more prominent pharmaceutical manufacturer while benefiting AbbVie by diversifying and expanding its portfolio.
“AbbVie’s acquisition of Cerevel strengthens our foundation in neuroscience and positions us to deliver sustainable long-term performance into the...
Today's Sponsors
Today's Sponsor